S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intouch Insight Ltd. stock logo
INX
Intouch Insight
C$0.40
-2.4%
C$0.42
C$0.32
C$0.49
C$10.21M1.4317,302 shs23,500 shs
Bio-Techne Co. stock logo
TECH
Bio-Techne
$62.76
+0.9%
$70.61
$51.79
$89.91
$9.87B1.221.06 million shs98,134 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intouch Insight Ltd. stock logo
INX
Intouch Insight
0.00%0.00%-6.98%-4.76%-8.05%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-0.83%-9.59%-12.08%-11.53%-26.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/AN/AN/AN/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.9704 of 5 stars
4.42.01.74.22.62.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.80
Moderate Buy$83.9033.68% Upside

Current Analyst Ratings

Latest INX, ABAL, DFX, and TECH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$85.00 ➝ $82.00
2/8/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$80.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$92.00 ➝ $87.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$85.00 ➝ $75.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$65.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intouch Insight Ltd. stock logo
INX
Intouch Insight
C$21.96M0.46C$0.03 per share12.22C$0.27 per share1.48
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.14B8.68$2.52 per share24.93$12.49 per share5.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/AN/A43.00N/A0.97%3.16%3.15%6/3/2024 (Estimated)
Bio-Techne Co. stock logo
TECH
Bio-Techne
$285.26M$1.3845.4834.487.0919.58%14.21%10.36%5/1/2024 (Confirmed)

Latest INX, ABAL, DFX, and TECH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.40N/A-$0.40N/AN/AN/A  
2/1/2024Q2 2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.36$0.33-$0.03$0.49$277.48 million$272.60 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.51%+151.98%23.19%N/A

Latest INX, ABAL, DFX, and TECH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.5%2/9/20242/12/20242/26/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intouch Insight Ltd. stock logo
INX
Intouch Insight
36.82
1.79
1.82
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.23
4.37
3.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Intouch Insight Ltd. stock logo
INX
Intouch Insight
29.70%
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Intouch Insight Ltd. stock logo
INX
Intouch Insight
N/A25.52 millionN/ANot Optionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,050157.19 million150.20 millionOptionable

INX, ABAL, DFX, and TECH Headlines

SourceHeadline
Which Is a Better Investment, Celldex Therapeutics, Inc. or BIO-TECHNE Corp Stock?Which Is a Better Investment, Celldex Therapeutics, Inc. or BIO-TECHNE Corp Stock?
aaii.com - April 19 at 9:13 AM
Which Is a Better Investment, Janux Therapeutics Inc or BIO-TECHNE Corp Stock?Which Is a Better Investment, Janux Therapeutics Inc or BIO-TECHNE Corp Stock?
aaii.com - April 19 at 9:13 AM
Bio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from AnalystsBio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 19 at 4:14 AM
Navigating 4 Analyst Ratings For Bio-TechneNavigating 4 Analyst Ratings For Bio-Techne
markets.businessinsider.com - April 18 at 2:43 PM
Bio-Techne (NASDAQ:TECH) Price Target Cut to $82.00 by Analysts at Deutsche Bank AktiengesellschaftBio-Techne (NASDAQ:TECH) Price Target Cut to $82.00 by Analysts at Deutsche Bank Aktiengesellschaft
marketbeat.com - April 18 at 8:35 AM
Bio-Techne Co. (NASDAQ:TECH) Shares Purchased by Cerity Partners LLCBio-Techne Co. (NASDAQ:TECH) Shares Purchased by Cerity Partners LLC
marketbeat.com - April 18 at 5:39 AM
SVB Wealth LLC Sells 25,151 Shares of Bio-Techne Co. (NASDAQ:TECH)SVB Wealth LLC Sells 25,151 Shares of Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 17 at 7:51 AM
Mackenzie Financial Corp Boosts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)Mackenzie Financial Corp Boosts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 16 at 9:27 AM
WCM Investment Management LLC Makes New $1.02 Million Investment in Bio-Techne Co. (NASDAQ:TECH)WCM Investment Management LLC Makes New $1.02 Million Investment in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 15 at 7:31 AM
Healthcare offers diversification from market hot spotsHealthcare offers diversification from market hot spots
livewiremarkets.com - April 14 at 11:26 PM
Cell Culture Market worth $57.9 billion by 2029 | MarketsandMarkets™Cell Culture Market worth $57.9 billion by 2029 | MarketsandMarkets™
theglobeandmail.com - April 12 at 9:51 AM
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTSBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
prnewswire.com - April 10 at 7:00 AM
New York State Teachers Retirement System Reduces Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)New York State Teachers Retirement System Reduces Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 10 at 5:35 AM
Allspring Global Investments Holdings LLC Raises Stock Position in Bio-Techne Co. (NASDAQ:TECH)Allspring Global Investments Holdings LLC Raises Stock Position in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 9 at 9:55 AM
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGYBIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
prnewswire.com - April 8 at 7:00 AM
Riverbridge Partners LLC Sells 15,014 Shares of Bio-Techne Co. (NASDAQ:TECH)Riverbridge Partners LLC Sells 15,014 Shares of Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 5 at 12:58 AM
Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic PositioningBuy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning
markets.businessinsider.com - April 4 at 12:26 PM
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial ExcellenceBio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
seekingalpha.com - April 4 at 8:43 AM
RedShiftBio Welcomes Sebastian Arevalo as New Sales LeaderRedShiftBio Welcomes Sebastian Arevalo as New Sales Leader
msn.com - April 3 at 1:35 PM
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCEBIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
finance.yahoo.com - April 3 at 8:34 AM
Bio-Techne (NASDAQ:TECH) shareholders have earned a 7.4% CAGR over the last five yearsBio-Techne (NASDAQ:TECH) shareholders have earned a 7.4% CAGR over the last five years
finance.yahoo.com - April 1 at 9:04 AM
BIO-TECHNE RECEIVES CiteAbS ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDSBIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
finance.yahoo.com - April 1 at 9:04 AM
Raymond James & Associates Boosts Stake in Bio-Techne Co. (NASDAQ:TECH)Raymond James & Associates Boosts Stake in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 1 at 4:24 AM
Bio-Techne Co. (NASDAQ:TECH) Shares Bought by Assenagon Asset Management S.A.Bio-Techne Co. (NASDAQ:TECH) Shares Bought by Assenagon Asset Management S.A.
marketbeat.com - March 30 at 4:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Intouch Insight logo

Intouch Insight

CVE:INX
Intouch Insight Ltd. develops managed mobile software applications and software-as-a-service platforms, and delivers data collection services to private businesses, governments, and regulators in Canada, the United States, and internationally. The company's software platforms include IntouchIntelligence, IntouchCapture, IntouchCheck, IntouchSurvey, and LiaCX that facilitate the development and delivery of data collection programs comprising mystery shopping, site adults, event lead capture, customer satisfaction surveys, mobile forms, checklists, and audits. It also develops customer experience management platform; and event marketing automation software. The company was formerly known as In-Touch Survey Systems Ltd. and changed its name to Intouch Insight Ltd. in July 2016. Intouch Insight Ltd. was founded in 1992 and is based in Ottawa, Canada.
Bio-Techne logo

Bio-Techne

NASDAQ:TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.